Noile-Immune Biotech Regains Rights to Solid Tumor Drug Candidates as Takeda Terminates License Deal
Noile-Immune Biotech Regains Rights to Solid Tumor Drug Candidates as Takeda Terminates License Deal
武田終止許可協議後，Noile-Immune Biotech 重獲實體瘤候選藥物的權利
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。